Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial.
Veenstra-VanderWeele J, Cook EH, King BH, Zarevics P, Cherubini M, Walton-Bowen K, Bear MF, Wang PP, Carpenter RL. Veenstra-VanderWeele J, et al. Among authors: walton bowen k. Neuropsychopharmacology. 2017 Jun;42(7):1390-1398. doi: 10.1038/npp.2016.237. Epub 2016 Oct 17. Neuropsychopharmacology. 2017. PMID: 27748740 Free PMC article. Clinical Trial.
Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.
Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ. Berry-Kravis EM, et al. Among authors: walton bowen k. Sci Transl Med. 2012 Sep 19;4(152):152ra127. doi: 10.1126/scitranslmed.3004214. Sci Transl Med. 2012. PMID: 22993294 Clinical Trial.
STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study.
Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH. Erickson CA, et al. Among authors: walton bowen k. J Autism Dev Disord. 2014 Apr;44(4):958-64. doi: 10.1007/s10803-013-1963-z. J Autism Dev Disord. 2014. PMID: 24272415 Clinical Trial.
Arbaclofen in fragile X syndrome: results of phase 3 trials.
Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M, Zarevics P, Walton-Bowen K, Wang P, Bear MF, Carpenter RL. Berry-Kravis E, et al. Among authors: walton bowen k. J Neurodev Disord. 2017 Jun 12;9:3. doi: 10.1186/s11689-016-9181-6. eCollection 2017. J Neurodev Disord. 2017. PMID: 28616094 Free PMC article.
Adaptive behavior in autism: Minimal clinically important differences on the Vineland-II.
Chatham CH, Taylor KI, Charman T, Liogier D'ardhuy X, Eule E, Fedele A, Hardan AY, Loth E, Murtagh L, Del Valle Rubido M, San Jose Caceres A, Sevigny J, Sikich L, Snyder L, Tillmann JE, Ventola PE, Walton-Bowen KL, Wang PP, Willgoss T, Bolognani F. Chatham CH, et al. Among authors: walton bowen kl. Autism Res. 2018 Feb;11(2):270-283. doi: 10.1002/aur.1874. Epub 2017 Sep 21. Autism Res. 2018. PMID: 28941213 Free PMC article.
Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.
Nelson H, Kemp J, Berger W, Corren J, Casale T, Dube L, Walton-Bowen K, LaVallee N, Stepanians M. Nelson H, et al. Among authors: walton bowen k. Ann Allergy Asthma Immunol. 2007 Aug;99(2):178-84. doi: 10.1016/S1081-1206(10)60642-4. Ann Allergy Asthma Immunol. 2007. PMID: 17718106 Clinical Trial.
20 results